ArticleAdvances in therapy2024

Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis.

Jesse Fishman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.